Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Sionna Therapeutics, Inc. SION NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
40/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$46.25
+2.6%

Sionna Therapeutics, Inc. (SION) is a Biotechnology company in the Healthcare sector, currently trading at $45.09. It has a SharesGrow Score of 39/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Analyst consensus target is SION = $46 (+2.6% upside).

Valuation: SION trades at a trailing Price-to-Earnings (P/E) of -19.9 (S&P 500 average ~25).

Net income is $75M (loss), growing at -23.3%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $9M against $307M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 20.61 (strong liquidity). Debt-to-assets is 2.7%. Total assets: $326M.

Analyst outlook: 2 / 3 analysts rate SION as buy (67%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 32/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 40/100 (Fail), Future 55/100 (Partial), Income ?/100 (Fail).

$46.25
▲ 2.57% Upside
Average Price Target
Based on 3 Wall Street analysts offering 12-month price targets for Sionna Therapeutics, Inc., the average price target is $46.25, with a high forecast of $58.00, and a low forecast of $24.00.
Highest Price Target
$58.00
Average Price Target
$46.25
Lowest Price Target
$24.00

SION SharesGrow Score Overview

48/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 32/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 55/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SION

✗
VALUE Fail
32/100
SION trades at a trailing Price-to-Earnings (P/E) of -19.9 (S&P 500 average ~25). Forward PEG -1.73 — Peter Lynch undervalued (≤1.0). Trailing PEG 3.19. Analyst consensus target is $46, implying +2% from the current price $45. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
SION: +0%/yr revenue is, -23.3%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet SION: Debt-to-Equity (D/E) ratio 0.03 (conservative), Current ratio is 20.61 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
SION: Gross margin is 0% (+0 pp trend), $2B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
55/100
Analyst outlook: 2 / 3 analysts rate SION as buy (67%). Analyst consensus target is $46 (+2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range7.255-45
Volume765.95K
Avg Volume (30D)310.35K
Market Cap$2.03B
Beta (1Y)4.04
Share Statistics
EPS (TTM)-1.88
Shares Outstanding$39.96M
IPO Date2025-02-07
Employees41
CEOMichael Cloonan
Financial Highlights & Ratios
Gross Profit$-647K
EBITDA$-88.34M
Net Income$-75.27M
Operating Income$-88.98M
Total Cash$235.88M
Total Debt$8.68M
Net Debt$-49.77M
Total Assets$325.95M
Price / Earnings (P/E)-24
Analyst Forecast
1Y Price Target$51.50
Target High$58.00
Target Low$24.00
Upside+14.2%
Rating ConsensusBuy
Analysts Covering3
Buy 67% Hold 0% Sell 33%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS8294011080

Price Chart

Track all markets on TradingView
SION
Sionna Therapeutics, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
7.26 52WK RANGE 45.00

People Also View

VERA
VERA
Vera Therapeutics, Inc.
$43.45
-2.05%
 CLDX
CLDX
Celldex Therapeutics, Inc.
$33.87
+1.62%
 ZYME
ZYME
Zymeworks Inc.
$27.73
+2.78%
 IMNM
IMNM
Immunome, Inc.
$23.39
+2.14%
 ARDX
ARDX
Ardelyx, Inc.
$6.30
-0.47%
 MAZE
MAZE
Maze Therapeutics, Inc.
$26.85
-3.00%
 ABCL
ABCL
AbCellera Biologics Inc.
$3.86
+2.66%
 BHVN
BHVN
Biohaven Ltd.
$10.37
-0.67%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message